TY - JOUR AU - Sah, Kailash Prasad AU - Saiju, Rohit AU - Roy, Pankaj AU - Kafle, Sonali PY - 2013/12/31 Y2 - 2024/03/28 TI - Retinoblastoma: Ten Years Experience at Kanti Children's Hospital JF - Journal of Nepal Medical Association JA - J Nepal Med Assoc VL - 52 IS - 192 SE - Original Article DO - 10.31729/jnma.2429 UR - https://www.jnma.com.np/jnma/index.php/jnma/article/view/2429 SP - AB - <p dir="LTR" align="JUSTIFY"><span style="font-family: Univers; font-size: xx-small;"><span style="font-family: Univers; font-size: xx-small;"><strong>Introduction: </strong></span></span><span style="font-family: Book Antiqua; font-size: xx-small;"><span style="font-family: Book Antiqua; font-size: xx-small;">Retinoblastoma is a malignant tumor of the embryonic neural retina. It is the most common intraocular tumor of childhood. It is a disease of early childhood with 80% cases diagnosed before the age of 4 years. The median age at diagnosis is 2 years. Bilateral cases are diagnosed earlier (median at 12 months and unilateral median age at 24 months). The incidence of retinoblastoma is approximately 1 in 15000-18000 live births in developed countries. The aim of the research is to study the clinical pathological features, treatment and survival of children with retinoblastoma over ten years. </span></span></p><p dir="LTR" align="JUSTIFY"><span style="font-family: Univers; font-size: xx-small;"><span style="font-family: Univers; font-size: xx-small;"><strong>Methods: </strong></span></span><span style="font-family: Book Antiqua; font-size: xx-small;"><span style="font-family: Book Antiqua; font-size: xx-small;">A retrospective hospital based study was conducted from March 1998 to February 2008. Gender, age, clinical presentation, pathology reports, treatment, follow –up and outcome were recorded at time of diagnosis. </span></span></p><p dir="LTR" align="JUSTIFY"><span style="font-family: Univers; font-size: xx-small;"><span style="font-family: Univers; font-size: xx-small;"><strong>Results: </strong></span></span><span style="font-family: Book Antiqua; font-size: xx-small;"><span style="font-family: Book Antiqua; font-size: xx-small;">A total of 42 children with retinoblastoma (85.7 % unilateral, 14.3% bilateral), with 50% having optic nerve involvement were studied. The most common presenting signs were extraoccular (28.6%), proptosis (23.8%), leukoria (23.8%), phthisis bulbi (16.7%), and strabismus (7.1%). The age at presentation ranged from 6-120 months with mean age of 46.6 months. The male to female ratio was 1.1:1.Two-thirds presented between 2-5 yrs, followed by 12-24 months (23.8%). Majority of children had poorly differentiated retinoblastoma (62 %), followed by well differentiated (28.6%), and moderately differentiated (9.5%). CEV based protocol used to treat, and over-all 10 yrs survival was 23.8 %, death 19 %, and lost to follow-up or left against medical advice 57.2%. </span></span></p><p dir="LTR" align="JUSTIFY"><span style="font-family: Univers; font-size: xx-small;"><span style="font-family: Univers; font-size: xx-small;"><strong>Conclusions:</strong></span></span><span style="font-family: Book Antiqua; font-size: xx-small;"><span style="font-family: Book Antiqua; font-size: xx-small;"> Despite severe resource limitation, pediatric oncology unit has been successfully treating retinoblastoma with the success rate of 23.8%.&nbsp;</span></span></p><p dir="LTR" align="JUSTIFY"><span style="color: #00adef; font-family: Book Antiqua; font-size: xx-small;"><span style="color: #00adef; font-family: Book Antiqua; font-size: xx-small;"><span style="color: #00adef; font-family: Book Antiqua; font-size: xx-small;"><strong>Keywords: </strong></span></span></span><span style="font-family: Book Antiqua; font-size: xx-small;"><span style="font-family: Book Antiqua; font-size: xx-small;">chemotherapy; outcome; remission; retinoblastoma.</span></span></p><p dir="LTR" align="CENTER">&nbsp;</p> ER -